The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...

Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on the ...

Spread the loveBoston Scientific, headquartered in Marlborough, has seen its stock surge by 50%, driven by a series of ...

Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...

SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the ...

Many climate-change experts say the second Trump administration's focus on the economy exposes Americans to more long-term ...

Trader Joe's is a great place to discover new products and enjoy the iconic vibe. Here's a look back at the history of the ...

Jayson Tatum traveled before making the deciding 3-pointer at the overtime buzzer to give the Boston Celtics a victory over ...

Group files civil rights complaint against Boston Public Schools over racially-segregated "affinity groups" teaching White ...